Quantcast

Latest Omalizumab Stories

2011-07-11 06:00:00

INCLINE VILLAGE, Nev., July 11, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced a favorable ruling today, specifically, that on July 7, 2011, the Second Judicial District Court of Nevada ruled in favor of PDL on two motions to dismiss filed by Genentech and F. Hoffmann LaRoche, Ltd. (Roche) in PDL's lawsuit related to the 2003 settlement agreement with Genentech. The court denied Genentech and Roche's motion to dismiss four of PDL's five claims for relief and,...

2011-05-06 15:13:07

Patients with severe allergic asthma that is inadequately controlled with the standard of care had improved symptoms and decreased flare-ups with injections of an antibody drug called omalizumab, according to experts at Baylor College of Medicine in a paper that appears in the current issue of Annals of Internal Medicine. "Many patients suffering from asthma who are being treated with the recommended inhaled corticosteroids and long-acting beta agonists continue to have asthma symptoms," said...

2011-05-06 06:30:00

SOUTH SAN FRANCISCO, Calif., May 6, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the company will assume development of R343, its inhaled syk inhibitor for allergic asthma that recently completed several Phase 1 clinical trials. Pfizer Inc. is returning full rights to the R343 program as a result of its decision to exit the allergy and respiratory therapeutic area within R&D. Rigel is evaluating the details of R343's development to date and...

2011-03-28 08:18:48

(Ivanhoe Newswire) -- A drug that targets the antibody immunoglobulin E (IgE), a key player in asthma, nearly eliminated seasonal increases in asthma attacks and decreased asthma symptoms among young people living in inner city environments, a clinical trial sponsored by the National Institutes of Health has found. This investigational use of the drug omalizumab, sold under the brand name Xolair, was conducted in eight U.S. cities by the Inner City Asthma Consortium (ICAC), a nationwide...

2011-03-22 12:37:50

Some 3 million children in the United States have some form of food allergy, ranging in severity from mild to life-threatening. Milk allergy is the most common, affecting 2.5 percent of children under age 3. In a small clinical study, immunologists and allergists at Children's Hospital Boston and the Stanford University School of Medicine report effectively desensitizing milk-allergic patients by increasing their exposure to milk in tandem with an allergy drug called omalizumab, allowing...

2011-03-17 12:38:55

Implications for treatment could impact school attendance, particularly in inner cities Stephen J. Teach, MD, MPH, Medical Director and Principal Investigator of IMPACT DC, a program of pediatric asthma care and research at Children's National Medical Center, served as the Site Principal Investigator for a new study that may advance asthma treatment and outcomes, specifically for inner-city children and teens. Findings from a clinical trial sponsored by the National Institutes of Health (NIH)...

2011-03-17 12:36:05

A new anti-asthma medication dramatically reduced increases in seasonal asthma attacks in children and young adults with allergic asthma, according to a multi-institutional study involving a UT Southwestern Medical Center physician. "The increased number of asthma attacks we typically see in the fall and spring nearly was eliminated in the children and adolescents who received the drug," said Dr. Rebecca Gruchalla, chief of allergy and immunology at UT Southwestern and a co-author of the...

2011-03-17 12:30:40

Researchers from Boston University School of Medicine (BUSM), in collaboration with researchers from the Inner City Asthma Consortium, have found that among inner-city children, the drug omalizumab improved asthma control, nearly eliminated seasonal exacerbations and reduced the need for controller medication. These findings appear in the March 17th issue of the New England Journal of Medicine. Guidelines-based treatment of persistent asthma follows a step-wise approach designed to achieve...

2011-03-17 12:25:01

Symptoms reduced in children and young people with moderate to severe disease A drug that targets the antibody immunoglobulin E (IgE), a key player in asthma, nearly eliminated seasonal increases in asthma attacks and decreased asthma symptoms among young people living in inner city environments, a clinical trial sponsored by the National Institutes of Health has found. The findings will appear in the March 17 issue of the New England Journal of Medicine. This investigational use of the drug...

2010-09-01 06:00:00

INCLINE VILLAGE, Nev., Sept. 1 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced revenue guidance for the third quarter ended September 30, 2010 of approximately $86 million, as compared with actual results of $71.4 million for the third quarter of 2009, a 20 percent year-over-year increase. The growth is primarily driven by increased second quarter 2010 sales of Avastin®, Herceptin®, Lucentis® and...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.